Radioembolization News and Research

RSS

A type of radiation therapy used to treat liver cancer that is advanced or has come back. Tiny beads that hold the radioisotope yttrium Y 90 are injected into the hepatic artery (the main blood vessel that carries blood to the liver).

Survival for patients with HCC increases with radioembolization

Analysis revealed survival for patients with hepatocellular carcinoma (HCC) is achievable using 90Y-resin microsphere radioembolization. The analysis conducted at multiple centers across Europe showed that the procedure is likely to provide survival benefit across different tumor stages, including patients with advanced liver cancer and with limited treatment options.

23 Aug 2011

MRG: Radioembolization is expected to grow from $50M in sales in 2011 to $128M in 2015

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, embolization particles will show the most significant growth, both in procedure volume and in revenue, among all devices in the transcatheter embolization and occlusion (TEO) market. Radioembolization is expected to grow from $50 million in sales in 2011 to $128 million in 2015, while drug-eluting beads will grow from $11 million to $28 million over the same period.

21 Apr 2011

Study: Y-90 radioembolization is a safe treatment for patients with liver cancer

Interventional radiologists have been the leaders in the use of intra-arterial yttrium-90 radioembolization, since its introduction in 2000, to treat liver cancer.

29 Mar 2011

FDA approves Nordion's TheraSphere IDE for Phase III trial to treat HCC

Nordion Inc., a leading provider of products and services to the global health science market, today announced that it has received U.S. Food and Drug Administration approval to conduct a Phase III clinical trial for TheraSphere® under an Investigational Device Exemption.

23 Mar 2011

Y-90 microspheres pack a therapeutic punch against late-stage liver cancer

The latest weapon against inoperable liver cancer is so tiny that it takes millions of them per treatment, but according to interventional radiologists at the Indiana University School of Medicine, those microscopic spheres really pack a therapeutic punch.

15 Dec 2010

China PharmaHub signs distribution agreement for radioactive glass sphere treatment for liver cancer

China PharmaHub Corp. ("PharmaHub"), which has recently merged with World Wide Relics which has changed its name to China PharmaHub Corp, and is in the process of obtaining approval from FINRA to trade under its new name with a new symbol, announced today that it has signed an Exclusive Distribution Agreement ("Agreement") with a world leader in precision glass technology which can be utilized to manufacture high precision radioactive glass spheres that emit alpha, beta or gamma radiation, either individually or in combination, for the treatment of malignant tumors of the liver.

26 Aug 2010

Two U.S. insurers approve coverage of radioembolization for treatment of unresectable liver cancer

MDS Nordion, a global leader in providing products and services for medical imaging and radiotherapeutics, today announced that two of the largest health insurers in the United States have recently approved coverage of radioembolization to treat unresectable liver cancer, which includes the use of MDS Nordion's TheraSphere(R) treatment. The two insurance companies and their affiliates together serve more than one-quarter of Americans and do business in all 50 states.

6 Feb 2010

New Jefferson trial to test radiation-emitting beads against advanced liver cancer

Liver cancer specialists at Jefferson's Kimmel Cancer Center in Philadelphia are beginning an 18-month study of a new treatment for liver cancer.

13 Feb 2008

Nonsurgical microspheres an option for liver cancer patients

A study in February’s Journal of Vascular and Interventional Radiology found that patients undergoing liver cancer treatment with Theraspheres?, radioactive microspheres containing Yittrium-90, can tolerate a 150 Gy single dose or 268 Gy repeated dose without risk of radiation-induced liver disease.

17 Feb 2005